Polarean Imaging Plc (POLX.L)
| Previous close | 1.8750 |
| Open | 1.8500 |
| Bid | 1.8000 x 0 |
| Ask | 1.8500 x 0 |
| Day's range | 1.8000 - 1.9300 |
| 52-week range | 0.8529 - 22.0000 |
| Volume | |
| Avg. volume | 18,606,119 |
| Market cap | 22.028M |
| Beta (5Y monthly) | 0.39 |
| PE ratio (TTM) | N/A |
| EPS (TTM) | -0.0400 |
| Earnings date | 05 Sept 2024 - 09 Sept 2024 |
| Forward dividend & yield | N/A (N/A) |
| Ex-dividend date | N/A |
| 1y target est | 0.08 |
Simply Wall St.Polarean Imaging Full Year 2023 Earnings: US$0.055 loss per share (vs US$0.066 loss in FY 2022)
Polarean Imaging ( LON:POLX ) Full Year 2023 Results Key Financial Results Revenue: US$890.9k (down 14% from FY 2022...
GlobeNewswirePolarean Raises $12.6 Million in Oversubscribed Financing Round to Accelerate XENOVIEW™ Commercialization and Strategic Growth Initiatives
Financing led by existing and new investors DURHAM, NC and LONDON, June 20, 2024 (GLOBE NEWSWIRE) -- Polarean Imaging plc (AIM: POLX) (“Polarean” or the “Company”), a commercial-stage medical device leader in advanced Magnetic Resonance Imaging (MRI) of the lungs, announces the closing of a $12.6 million oversubscribed financing via the Alternative Investment Market (AIM) of the London Stock Exchange. The fundraise was co-led by strategic investors NUKEM Isotopes GmbH and Bracco S.p.A., in addit
- GlobeNewswire
Polarean’s Xenon MRI to be Featured at Upcoming ATS 2024 Conference
Featured Company at Respiratory Innovation Summit to Jump Start Robust PresenceDURHAM, NC and LONDON, May 08, 2024 (GLOBE NEWSWIRE) -- Polarean (AIM: POLX), a commercial-stage medical device leader in advanced magnetic resonance imaging (MRI) of the lungs, has been selected as one of the featured companies and a poster presenter at the American Thoracic Society’s (ATS) 2024 Respiratory Innovation Summit (RIS), a testament to the value of our XENOVIEW technology seen across lung clinicians and pu
